Rational development of multicomponent mRNA vaccine candidates against mpox
| Autor: | Rong-Rong Zhang, Zheng-Jian Wang, Yi-Long Zhu, Wei Tang, Chao Zhou, Suo-Qun Zhao, Mei Wu, Tao Ming, Yong-Qiang Deng, Qi Chen, Ning-Yi Jin, Qing Ye, Xiao Li, Cheng-Feng Qin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Emerging Microbes and Infections, Vol 12, Iss 1 (2023) |
| Druh dokumentu: | article |
| ISSN: | 22221751 2222-1751 |
| DOI: | 10.1080/22221751.2023.2192815 |
| Popis: | ABSTRACTThe re-emerging mpox (formerly monkeypox) virus (MPXV), a member of Orthopoxvirus genus together with variola virus (VARV) and vaccinia virus (VACV), has led to public health emergency of international concern since July 2022. Inspired by the unprecedent success of coronavirus disease 2019 (COVID-19) mRNA vaccines, the development of a safe and effective mRNA vaccine against MPXV is of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we rationally constructed and prepared a panel of multicomponent MPXV vaccine candidates encoding different combinations of viral antigens including M1R, E8L, A29L, A35R, and B6R. In vitro and in vivo characterization demonstrated that two immunizations of all mRNA vaccine candidates elicit a robust antibody response as well as antigen-specific Th1-biased cellular response in mice. Importantly, the penta- and tetra-component vaccine candidates AR-MPXV5 and AR-MPXV4a showed superior capability of inducing neutralizing antibodies as well as of protecting from VACV challenge in mice. Our study provides critical insights to understand the protection mechanism of MPXV infection and direct evidence supporting further clinical development of these multicomponent mRNA vaccine candidates. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|